In last trading session, Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) saw 0.59 million shares changing hands with its beta currently measuring 1.75. Company’s recent per share price level of $33.82 trading at $1.36 or 4.19% at ring of the bell on the day assigns it a market valuation of $2.00B. That closing price of RYTM’s stock is at a discount of -3.46% from its 52-week high price of $34.99 and is indicating a premium of 54.17% from its 52-week low price of $15.50. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.82 million shares which gives us an average trading volume of 596.40K if we extend that period to 3-months.
For Rhythm Pharmaceuticals Inc. (RYTM), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.68 in the current quarter.
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) trade information
Upright in the green during last session for gaining 4.19%, in the last five days RYTM remained trading in the green while hitting it’s week-highest on Friday, 11/17/23 when the stock touched $33.82 price level, adding 0.56% to its value on the day. Rhythm Pharmaceuticals Inc.’s shares saw a change of 16.14% in year-to-date performance and have moved 18.83% in past 5-day. Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) showed a performance of 52.27% in past 30-days. Number of shares sold short was 11.65 million shares which calculate 24.74 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $40.56 to the stock, which implies a rise of 16.62% to its current value. Analysts have been projecting $29.00 as a low price target for the stock while placing it at a high target of $70.00. It follows that stock’s current price would drop -106.98% in reaching the projected high whereas dropping to the targeted low would mean a gain of 14.25% for stock’s current value.
Rhythm Pharmaceuticals Inc. (RYTM) estimates and forecasts
Statistics highlight that Rhythm Pharmaceuticals Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 101.67% of value to its shares in past 6 months, showing an annual growth rate of 7.49% while that of industry is 14.80. Apart from that, the company came raising its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 9.30% in the current quarter and calculating 27.20% increase in the next quarter. This year revenue growth is estimated to rise 236.40% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $26.35 million for the same. And 5 analysts are in estimates of company making revenue of $28.21 million in the next quarter that will end on Mar 2024. Company posted $8.79 million and $11.47 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 199.80% while estimating it to be 146.00% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -4.19% during past 5 years. In 2023, company’s earnings growth rate is likely to be around 8.68% while estimates for its earnings growth in next 5 years are of -9.00%.
Rhythm Pharmaceuticals Inc. is more likely to be releasing its next quarterly report on November 07 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.